Current Therapeutic Paradigms in Glioblastoma
Current Therapeutic Paradigms in Glioblastoma
复制标题
DOI：
10.2174/157488710790820544
复制
发表时间：
2010-01-01
影响因子：
1.9
通讯作者：
Mehta, Minesh
中科院分区：
文献类型：
--
作者：
Quick, Allison;Patel, Disha;Mehta, Minesh
胶质母细胞瘤（GBM）是一种WHO IV级恶性胶质瘤，是最常见和致命的成人原发性脑肿瘤。中位生存率范围为12-15个月。目前GBM的标准治疗已经从切除术后辅助放疗发展到切除术、同时辅助化疗（替莫唑胺）和放疗以及额外的辅助化疗。特定分子生物标志物的表达，特别是O-6 -甲基鸟嘌呤甲基转移酶（MGMT）状态，可能决定肿瘤对治疗的反应，并有助于确定该方案的获益程度。通过在分子水平上进一步鉴定GBM的生物学亚型，可以开发特异性靶向治疗，并在未来用于更个性化的治疗方案。本文将对GBM的治疗现状及新的分子靶向治疗方法，如EGFR抑制剂、mTOR/PI 3激酶抑制剂、抗血管生成药物的研究进展进行综述。
Glioblastoma (GBM), a WHO grade IV malignant glioma, is the most common and lethal adult primary brain tumor. Median survival rates range from 12-15 months. The current standard of care for GBM has evolved from resection followed by adjuvant radiotherapy to resection, concurrent adjuvant chemotherapy (temozolomide) and radiation, and additional adjuvant chemotherapy. The expression of specific molecular biomarkers, especially O-6 -methylguanine methyltransferase (MGMT) status, may determine the response of the tumor to treatment, and helps in identifying the magnitude of benefit from this regimen. By identifying further biological subtypes of GBM at the molecular level, specific targeted therapies could be developed and used in the future for more individualized therapeutic regimens. This article will review the current therapies for GBM and the investigation of new molecular and targeted therapies, such as EGFR inhibitors, mTOR/PI3Kinase inhibitors, and anti-angiogenesis agents.